AbbVie Inc. (ABBV)
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV's valuation remains attractive; a 14.4x FY 2027 multiple is compelling if earnings materialize, with technicals supporting a bullish breakout. Risks include Humira revenue erosion, pipeline uncertainty, and debt burden, but ABBV's clean loss-of-exclusivity profile and robust FCF yield support GARP status.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.
Is AbbVie a Buy, Sell, or Hold in 2026?
AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected.
The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio
AbbVie headlines today's top stock reports as Zacks highlights pharma recovery, resilient beverages and Chevron???s evolving energy outlook.
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
5 Big Drug Stocks That May Continue to Outperform in 2026
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
How AbbVie's Pipeline Is Lining Up Key Product Launches
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
